Claims for Patent: 7,094,874

✉ Email this page to a colleague

Summary for Patent: 7,094,874

Title:	Soluble CTLA4 mutant molecules
Abstract:	The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Inventor(s):	Robert J. Peach, Joseph Roy Naemura, Peter S. Linsley, Jurgen Bajorath
Assignee:	Bristol Myers Squibb Co
Application Number:	US09/865,321

Details for Patent 7,094,874

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bristol-myers Squibb Company	ORENCIA	abatacept	For Injection	125118	December 23, 2005	7,094,874	2021-05-23
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	July 29, 2011	7,094,874	2021-05-23
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	June 07, 2016	7,094,874	2021-05-23
Bristol-myers Squibb Company	ORENCIA	abatacept	Injection	125118	March 30, 2017	7,094,874	2021-05-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.